Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 7pembrolizumab 6olaparib 5Carboplatin 4Bevacizumab 4tisotumab vedotin 2niraparib 2mirvetuximab soravtansine 2durvalumab 2defactinib 2Topotecan 2Taxes 2Saline Solution 2Immunoglobulin G 2Disulfides 2Cisplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sodium thiosulfate 1sapanisertib 1sacituzumab govitecan 1rucaparib 1relatlimab 1relacorilant 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Glucose × Gynecologic × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡